DBVT

DBVB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment AI

B+

Bull case

20%

Probability

Target price

$46.22

+153.5% vs current

Most likely

Base case

60%

Probability

Target price

$35.38

+94.1% vs current

B-

Bear case

20%

Probability

Target price

$7.87

-56.8% vs current

AI sentiment snapshot

Latest data as of 2026-01-20

AI commentary

Market sentiment is cautiously optimistic: the analyst median sits materially above the anchor while coverage shows a wide low–high spread, reflecting binary clinical/regulatory risk [#SERP-1] [#SERP-7]. Near-term tone will hinge on upcoming readouts and regulatory signals; positive results could trigger rapid re-rating while adverse outcomes risk sharp drawdown.

RankAlpha Sentiment AI - 2026-01-20

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-04-20catalystInterim clinical readout for lead EPIT programHigh impact

Planned interim efficacy/safety readout for lead EPIT program; market likely to reprice on topline binary results (timing estimated) [#SERP-1].

2026-12-31eventRegulatory interaction / filing milestoneHigh impact

Potential regulatory filing or major agency interaction for peanut EPIT; assumed window end used for planning purposes [#SERP-3].

2027-01-20catalystCommercial partnerships and early launch progressHigh impact

Progress on commercialization or partner deals that could materially increase revenue scale over time; execution and uptake risk remains [#SERP-7].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-01-20 • Updated nightlySource: Internal modelMethodology